Analysis of Cytotoxic Activity of the CD4+ T Lymphocytes Generated by Local Immunotherapy

Overview

Journal Br J Cancer

Specialty Oncology

Date 1996 Jan 1

PMID 8554971

Citations 3

Authors

Y Katsumoto

T Monden

T Takeda

A Haba

Y Ito

E Wakasugi

T Wakasugi

M Sekimoto

T Kobayashi

H Shiozaki

T Shimano

M Monden

Affiliations

Soon will be listed here.

Abstract

We previously reported that the anti-tumour effect of OK-432 is considerably enhanced by its intratumoral injection together with fibrinogen. In the present study, we generated killer T cells by culturing tumour-infiltrating lymphocytes from thyroid cancer patients who had received this local immunotherapy. Phenotypic analysis revealed that the T cells were positive for CD3+, CD4+, Leu8-, CD45RO+ and T-cell receptor (TCR)alpha beta+, as well as showing strong surface expression of HLA-DR, CD25, LFA-1 and ICAM-1. The generated CD4+ T cells secreted interferon (IFN)-gamma, tumour necrosis factor (TNF)-alpha, TNF-beta, and interleukin (IL)-6 (but not IL-4), and exhibited a high level of cytolytic activity against several tumour cell lines. The cytolytic activity of these T cells for Daudi cells was inhibited by preincubation with an anti-intercellular adhesion molecule (ICAM)-1 antibody, but not by preincubation with anti-TCR alpha beta, anti-CD2, or anti-LFA-1 antibodies. Pretreatment with anti-ICAM-1 antibody inhibited T-cell cytolytic activity, but not conjugation with target cells. In addition, incubation with immobilised anti-ICAM-1 enhanced the secretion of IFN-gamma by T cells. We conclude that ICAM-1 expressed on the effector cytotoxic CD4+ T lymphocytes delivers regulatory signals that enhance IFN-gamma secretion.

Citing Articles

Differential distribution and prognostic value of CD4 T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes.

Shi Z, Zhang S, Li C, Fan D, Xue Y, Cheng Z Front Immunol. 2022; 13:966550.

PMID: 36091039 PMC: 9459039. DOI: 10.3389/fimmu.2022.966550.

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.

Neeley Y, McDonagh K, Overwijk W, Restifo N, Sanda M Prostate. 2002; 53(3):183-91.

PMID: 12386918 PMC: 2042541. DOI: 10.1002/pros.10136.

Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.

DAngelica M, Tung C, Allen P, Halterman M, Delman K, Delohery T Mol Med. 1999; 5(9):606-16.

PMID: 10551902 PMC: 2230459.

References

Watanabe Y, IWA T . Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Mod. 1987; 6(2):169-80. View

Rosenberg S, Spiess P, Lafreniere R . A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233(4770):1318-21. DOI: 10.1126/science.3489291. View

Marvel J, Mayer A . CD45R gives immunofluorescence and transduces signals on mouse T cells. Eur J Immunol. 1988; 18(5):825-8. DOI: 10.1002/eji.1830180526. View

Denning S, Dustin M, Springer T, Singer K, Haynes B . Purified lymphocyte function-associated antigen-3 (LFA-3) activates human thymocytes via the CD2 pathway. J Immunol. 1988; 141(9):2980-5. View

Ozaki S, Suginoshita T . Biological response modifier as antigen: OK432-specific T-cell clone as an anti-tumor effector cell. Cell Immunol. 1989; 120(2):477-81. DOI: 10.1016/0008-8749(89)90215-3. View

Wacholtz M, Patel S, Lipsky P . Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med. 1989; 170(2):431-48. PMC: 2189396. DOI: 10.1084/jem.170.2.431. View

Noguchi M, Hozumi N, Nisbet-Brown E . CD4+ cytolytic T cell clones restricted to HLA class II, DR beta I, and DR beta III chains. Cell Immunol. 1989; 123(1):96-107. DOI: 10.1016/0008-8749(89)90271-2. View

Ju S, Ruddle N, Strack P, Dorf M, DeKruyff R . Expression of two distinct cytolytic mechanisms among murine CD4 subsets. J Immunol. 1990; 144(1):23-31. View

Erb P, Grogg D, Troxler M, Kennedy M, Fluri M . CD4+ T cell-mediated killing of MHC class II-positive antigen-presenting cells. I. Characterization of target cell recognition by in vivo or in vitro activated CD4+ killer T cells. J Immunol. 1990; 144(3):790-5. View

10.

Ozaki S, Suginoshita T, Watanabe T, Obayashi H . Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells. Cancer Res. 1990; 50(15):4630-4. View

11.

Springer T . Adhesion receptors of the immune system. Nature. 1990; 346(6283):425-34. DOI: 10.1038/346425a0. View

12.

Moingeon P, Lucich J, Stebbins C, Recny M, Wallner B, Koyasu S . Complementary roles for CD2 and LFA-1 adhesion pathways during T cell activation. Eur J Immunol. 1991; 21(3):605-10. DOI: 10.1002/eji.1830210311. View

13.

van Seventer G, Shimizu Y, Horgan K, Luce G, Webb D, Shaw S . Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation. Eur J Immunol. 1991; 21(7):1711-8. DOI: 10.1002/eji.1830210719. View

14.

Romagnani S . Human TH1 and TH2 subsets: doubt no more. Immunol Today. 1991; 12(8):256-7. DOI: 10.1016/0167-5699(91)90120-I. View

15.

Wierenga E, Snoek M, Jansen H, Bos J, van Lier R, Kapsenberg M . Human atopen-specific types 1 and 2 T helper cell clones. J Immunol. 1991; 147(9):2942-9. View

16.

Nagaoka H, Monden T, Sakita I, Katsumoto Y, Wakasugi T, Kawasaki Y . Establishment of cytotoxic CD4+ T cell clones from cancer patients treated by local immunotherapy. Biotherapy. 1992; 5(4):241-50. DOI: 10.1007/BF02179041. View

17.

Yagyu T, Monden T, Baba M, Tamaki Y, Takeda T, Kobayashi T . A cancer-reactive human monoclonal antibody derived from a colonic cancer patient treated with local immunotherapy. Jpn J Cancer Res. 1993; 84(1):75-82. PMC: 5919026. DOI: 10.1111/j.1349-7006.1993.tb02787.x. View

18.

Apasov S, Redegeld F, Sitkovsky M . Cell-mediated cytotoxicity: contact and secreted factors. Curr Opin Immunol. 1993; 5(3):404-10. DOI: 10.1016/0952-7915(93)90060-6. View

19.

Oka Y, Kobayashi T, Fujita S, Matsuura N, Okamoto S, Asakawa H . Establishment of a human anaplastic thyroid cancer cell line secreting granulocyte colony-stimulating factor in response to cytokines. In Vitro Cell Dev Biol Anim. 1993; 29A(7):537-42. DOI: 10.1007/BF02634147. View

20.

Sakita I, Monden T, Nagaoka H, Katsumoto Y, Wakasugi T, Tomita N . Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy. Biotherapy. 1993; 6(2):103-12. DOI: 10.1007/BF01877423. View